CoronaVac
- Generic Name
- CoronaVac
- Drug Type
- Biotech
- Unique Ingredient Identifier
- M1QXB372B8
- Background
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.
Sinovac Launches Phase III Trial of Bivalent HFMD Vaccine
• Sinovac Biotech has initiated a Phase III clinical trial for its bivalent vaccine targeting Hand Foot and Mouth Disease (HFMD).
• The trial will assess the vaccine's efficacy, safety, and immunogenicity in infants and young children aged 6 to 71 months.
• This marks the first Phase III trial globally for a multivalent vaccine against HFMD, caused by Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16).
• Sinovac is also developing a tetravalent vaccine against HFMD, expanding protection against additional enterovirus strains.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath